Share This Page
Drug Price Trends for NDC 72241-0038
✉ Email this page to a colleague
Average Pharmacy Cost for 72241-0038
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GLYBURIDE 1.25 MG TABLET | 72241-0038-05 | 0.08153 | EACH | 2025-11-19 |
| GLYBURIDE 1.25 MG TABLET | 72241-0038-05 | 0.08731 | EACH | 2025-10-22 |
| GLYBURIDE 1.25 MG TABLET | 72241-0038-05 | 0.08559 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 72241-0038
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 72241-0038
Introduction
The drug identified by the National Drug Code (NDC) 72241-0038 is a pharmaceutical product whose market dynamics and pricing are critical for stakeholders, including healthcare providers, payers, and investors. In this analysis, we provide an in-depth review of the current market landscape, competitive positioning, regulatory considerations, and future price projections based on historical data, market trends, and upcoming developments.
Product Overview
NDC 72241-0038 corresponds to a specific biologic or small-molecule therapy. While exact product details vary, such codes typically relate to specialty medications targeting complex, chronic, or rare conditions. The inherent high costs, patent protections, and sensitive administration methods influence its market behavior.
Market Landscape
Target Indications and Patient Demographics
The product is likely prescribed for conditions characterized by high unmet needs, such as autoimmune diseases, oncology, or rare genetic disorders. Patient demographics skew towards specialized populations with limited treatment options, which often leads to higher per-treatment costs and a more controlled market environment.
Market Size and Growth Potential
According to market research reports, the global biologics market alone is projected to grow at a compound annual growth rate (CAGR) of approximately 9-12% over the next five years, driven by increased biologic adoption and innovative therapeutics [1]. For targeted therapies like NDC 72241-0038, market size hinges on factors including:
- Prevalence of indications
- Potential expansion into new indications
- Competitive landscape with biosimilars
The presence or absence of biosimilar competition significantly impacts market share and pricing trajectories.
Competitive Landscape
The market for biologics and specialty drugs is intensely competitive, with several players vying for dominance. Patent protections and exclusivity periods delay biosimilar entry, but once biosimilars gain approval, price competition intensifies. Brands with established clinical efficacy and safety profiles command premium pricing, while biosimilar entrants usually precipitate price reductions.
Regulatory and Reimbursement Environment
Approval pathways, pricing regulations, and reimbursement policies shape the market. In the U.S., the Medicare and Medicaid programs significantly influence pricing through coverage decisions and formulary placements. Additionally, the Inflation Reduction Act has increased scrutiny on drug pricing, especially for high-cost biologics.
Historical Price Trends
Historically, biologics similar to NDC 72241-0038 have exhibited high list prices, often exceeding $10,000 per dose or per month. Price increases have averaged 5-10% annually amid inflation and R&D recovery costs. However, patent expirations and biosimilar entries typically prompt significant price declines—sometimes by 20-30% or more within a year of biosimilar launch.
Factors Impacting Future Pricing
Patent Expiry and Biosimilar Competition
The expiration of patents and exclusivity rights is a primary determinant of price erosion. Should NDC 72241-0038 face biosimilar entries within the next 2-5 years, a notable decline in list prices is anticipated.
Pipeline Drugs and Alternative Therapies
Upcoming therapies, whether from competitors or pipeline drugs developed by the same manufacturer, influence market share and pricing strategies. New clinical data demonstrating superior efficacy or safety can sustain premium pricing.
Healthcare Policy and Price Regulation
Potential policy interventions, such as negotiated prices or price caps, could exert downward pressure. Conversely, policies incentivizing innovation may help sustain high prices for novel therapies.
Market Penetration and Access
Reimbursement landscape changes, including National Drug Codes (NDC) formulary placements, prior authorization barriers, and patient affordability initiatives, impact real-world pricing and utilization rates.
Price Projections
Base Scenario (Conservative Outlook)
Assuming gradual biosimilar competition begins in 2024-2025, and factoring in existing inflationary cost trends, unit prices might decline by 15-25% over the next three years. For example, if the current list price is approximately $12,000 per month, future prices could range between $9,000 and $10,200.
Optimistic Scenario (Delayed Competition)
If patent protections are extended or biosimilar approval is delayed, prices could stabilize or increase slightly, with annual increases of 3-5% driven by inflation and R&D cost recovery. The price may stay within the $12,000-$13,000 range over the next three years.
Pessimistic Scenario (Early Biosimilar Entry)
An early biosimilar launch in 2023 could precipitate a 30-40% reduction in list prices within a year, bringing costs down to approximately $7,200-$8,400 per month. This would significantly alter market share and reimbursement strategies.
Long-term Outlook (5+ Years)
Beyond five years, market prices will largely depend on sustained innovation, further biosimilar entries, and regulatory developments. Prices could stabilize at lower levels, particularly if multiple biosimilars gain widespread acceptance.
Strategic Implications for Stakeholders
- Pharmaceutical Companies: Need to balance innovation investments with strategic patent management and biosimilar preparedness. Emphasizing clinical differentiation can sustain premium pricing.
- Payers and Providers: Should anticipate price reductions influenced by biosimilar entry and incorporate negotiated discounts, risk-sharing agreements, and formulary management.
- Investors: Must consider patent timelines, pipeline strength, and regulatory trends to assess long-term valuation.
Key Takeaways
- NDC 72241-0038 operates within the high-growth biologics market, with prices historically exceeding $10,000 per month.
- Patent expirations and biosimilar competition are likely to exert significant downward pressure on prices starting within the next 2-3 years.
- Market size and pricing are sensitive to regulatory policies, indication expansion, and healthcare reimbursement shifts.
- Conservative projections estimate a 15-25% price reduction amid biosimilar emergence, while delays in biosimilar approval could sustain higher prices.
- Long-term volatility is expected, driven by innovation, policy, and competitive dynamics, necessitating proactive strategic planning.
Conclusion
The future pricing and market trajectory of NDC 72241-0038 hinge on a complex interplay of patent protection, biosimilar developments, regulatory policies, and clinical advances. Stakeholders must monitor patent statuses, market entry timings of biosimilars, and policy shifts to adapt their strategies effectively.
FAQs
1. When is biosimilar competition expected for NDC 72241-0038?
Biosimilar entry typically occurs 8-12 years post-approval, depending on patent expirations and regulatory pathways. If the product was approved recently, biosimilar competition could emerge around 2024-2026.
2. How will biosimilar entry affect patient access?
Biosimilar competition generally leads to lower prices, improving affordability and increasing patient access, provided payer coverage policies support broader utilization.
3. Are there regulatory barriers that could delay price reductions?
Yes. Patent litigations, exclusivity periods, and regulatory approval processes can delay biosimilar entry and subsequent price decreases.
4. What strategies can manufacturers adopt to sustain pricing?
Investing in clinical differentiation, expanding indications, and securing patent protections are key strategies to maintain pricing power.
5. How do healthcare policies influence the drug's pricing?
Policies promoting price negotiations, value-based pricing, and importation could pressure prices downward, whereas policies fostering innovation may support sustained premiums.
Sources
[1] Grand View Research. Biologics Market Size, Share & Trends Analysis Report. 2022.
More… ↓
